Menu
You have to log in or sign up before you can proceed.
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€7.10

€7.10

-2.140%
-0.155
-2.140%
-
 
09:21 / Tradegate WKN: A0Q6J0 / Name: Zur Rose Group / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15
JavaScript chart by amCharts 3.21.15JS chart by amCharts
Select a timeframe to show chart data
From: to:
Zoom:
Loading data...

Financial data and news for Zur Rose Group

sharewise wants to provide you with the best news and tools for Zur Rose Group, so we directly link to the best financial data sources.

News

DocMorris AG announces number of shares sold in rights offering
DocMorris AG announces number of shares sold in rights offering
DocMorris AG announces number of shares sold in rights offering
Pelion invests in DocMorris
Pelion invests in DocMorris
Pelion invests in DocMorris
DocMorris AG shareholders approve capital increase and all proposals put forward by the Board of Directors
DocMorris AG shareholders approve capital increase and all proposals put forward by the Board of Directors
DocMorris AG shareholders approve capital increase and all proposals put forward by the Board of Directors
DocMorris announces final details on the agenda of today's Annual General Meeting and the planned capital increase
DocMorris announces final details on the agenda of today's Annual General Meeting and the planned capital increase
DocMorris announces final details on the agenda of today's Annual General Meeting and the planned capital increase
DocMorris accelerates Rx growth to 52 per cent and secures CHF 200 million capital increase through firm underwriting
DocMorris accelerates Rx growth to 52 per cent and secures CHF 200 million capital increase through firm underwriting
DocMorris accelerates Rx growth to 52 per cent and secures CHF 200 million capital increase through firm underwriting
DocMorris achieves 2024 targets, expects Rx growth of around 50 per cent in the first quarter of 2025 and plans capital increase
DocMorris achieves 2024 targets, expects Rx growth of around 50 per cent in the first quarter of 2025 and plans capital increase
DocMorris achieves 2024 targets, expects Rx growth of around 50 per cent in the first quarter of 2025 and plans capital increase
DocMorris AG: ECJ Ruling on advertising for prescription medicines
DocMorris AG: ECJ Ruling on advertising for prescription medicines
DocMorris AG: ECJ Ruling on advertising for prescription medicines
DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter
DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter
DocMorris grows 6.7 per cent in 2024 and accelerates Rx growth in the fourth quarter